FAQ

Anti-prolactin Receptor Antibody LFA102

Known as: LFA102 
A neutralizing antibody against the prolactin receptor (PRLR) with potential antineoplastic activity. Upon administration, anti-prolactin receptor… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2016
0120122016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
In the era of precision medicine, the identification of new targets is a constant challenge to improve cancer therapy… (More)
Is this relevant?
2016
2016
Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer
LESSONS LEARNED Despite evidence for a role for prolactin signaling in breast and prostate tumorigenesis, a prolactin receptor… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2013
2013
Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer.
Numerous lines of evidence suggest that the polypeptide hormone prolactin (PRL) may contribute to breast and prostate… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2013
Review
2013
Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer.
The prolactin (PRL)-prolactin receptor (PRLR) signaling complex has been implicated in the pathology of breast and prostate… (More)
  • figure 1
  • figure 2
Is this relevant?
2013
2013
Molecular Pathways Molecular Pathways: Blockade of the PRLR Signaling Pathway as a Novel Antihormonal Approach for the Treatment of Breast and Prostate Cancer
The prolactin (PRL)–prolactin receptor (PRLR) signaling complex has been implicated in the pathology of breast and prostate… (More)
  • figure 1
  • figure 2
Is this relevant?
Review
2012
Review
2012
TITLE: Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, A Novel Potential Therapeutic for the Treatment of Breast Cancer AUTHORS AND AFFILIATIONS:
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Numerous lines of… (More)
  • table 1
Is this relevant?